Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 109Uterine Cervical Neoplasms 57Endometrial Neoplasms 38Fallopian Tube Neoplasms 34Carcinoma, Ovarian Epithelial 27Breast Neoplasms 25Neoplasms 15Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 12Uterine Cervical Dysplasia 11Recurrence 11Stomach Neoplasms 10Neoplasm Metastasis 10Lung Neoplasms 9Colorectal Neoplasms 9Uterine Neoplasms 8Triple Negative Breast Neoplasms 8Sarcoma 8Urinary Bladder Neoplasms 7Melanoma 6Esophageal Neoplasms 6Vulvar Neoplasms 5Vaginal Neoplasms 5Testicular Neoplasms 5Lymphoma, Non-Hodgkin 5Small Cell Lung Carcinoma 4Sezary Syndrome 4Rectal Neoplasms 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4

Interventions

anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Platinum-resistant Ovarian Cancer × Gynecologic × Clear all
NCT05736952 2023-05-11

Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Withdrawn
Gynecologic

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡